InhaleRx's IRX-211 Receives Approval for Phase II Breakthrough Cancer Pain Trial; Neurotech's NTI164 Shows Promise in PANDAS/PANS
核心洞察
InhaleRx (搜索)'s IRX-211 drug-device combination has been approved for a Phase II clinical trial to treat breakthrough cancer pain (搜索) (BTcP) in patients, addressing a critical need for non-opioid options.
The trial will assess the safety, efficacy, and optimal dosing of IRX-211, aiming to provide rapid and reliable pain relief without the severe side effects associated with opioid-based treatments.
Neurotech International (搜索)'s NTI164 cannabinoid drug candidate demonstrated modulation of the immune system and epigenetic factors in children with PANDAS/PANS in a Phase I/II trial.
InhaleRx (搜索) has received approval from the Human Research Ethics Committee (HREC) to commence a Phase II clinical trial for its IRX-211 drug-device medication, targeting patients suffering from breakthrough cancer pain (搜索) (BTcP). This trial aims to evaluate the safety, efficacy, and dosing of IRX-211 in managing BTcP, an acute and intense pain that significantly impacts the lives of cancer patients and is often challenging to manage with conventional pain therapies.
InhaleRx's IRX-211 Trial Details
BTcP affects a substantial portion of cancer patients globally, with an estimated total addressable market exceeding US$1 billion, according to InhaleRx (搜索). The trial represents a significant step toward providing a non-opioid alternative for pain management. Darryl Davies, CEO of InhaleRx, stated that "IRX-211 has the potential to redefine how breakthrough cancer pain (搜索) is managed, addressing a critical gap in the market currently for safe, fast-acting, non-opioid treatments." He further emphasized the company's commitment to delivering a therapeutic solution that offers reliable relief without the dependency risks and severe side effects linked to opioid-based treatments like fentanyl.
Neurotech International's NTI164 in PANDAS/PANS
Neurotech International (搜索) has announced the results of genomic analysis from a Phase I/II clinical trial of its NTI164 cannabinoid drug candidate in patients with Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (搜索) (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (搜索) (PANS). The study revealed that NTI164 modulates the immune system, protein translation, and epigenetic factors at both the gene expression (genomic) and protein (proteomic) levels in children with PANDAS/PANS.
The data indicates that NTI164 is safe and effective under the inflammatory conditions characteristic of PANDAS/PANS, with no activation of potentially damaging cellular pathways. Neurotech anticipates compiling and submitting the genomic analysis results to a leading scientific journal in the near future.